spacer
home > epc > autumn 2003 > driving patient compliance
PUBLICATIONS
European Pharmaceutical Contractor

Driving Patient Compliance

The Scope of the Problem

Non-compliance commonly refers to the failure of patients to take medicines in their prescribed manner. Recognised as a serious health care issue, studies show that patient non-compliance can range from 20-80 per cent depending on the type of treatment being taken (1). The problem of non-compliance is not a new one and has been investigated for several decades worldwide.

The Consequences

Patient non-compliance lessens the quality of health care and can lead to dangerous consequences for patients. In the US, it has been estimated that non-compliance causes 340 deaths per day and is responsible for 10-25 per cent of hospital and nursing home admissions. Patient non-compliance is taken so seriously in the US that the New York Times dubbed it the nation's 'other drug problem' (2).

In a recent study conducted by Dendrite's Analytika Division, based on an analysis of data from nearly half of the US retail chain and independent companies, it was discovered that 'fewer than one in four patients on a cholesterol-lowering therapy completes a full year of treatment' (3). For the pharma industry, this gap between compliance and persistence translates into vast amounts of lost revenue.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Pietro Bonacossa, Marketing Executive, and Dr Faiz Kermani, Budgets, Proposals and Marketing Executive at Chiltern International Inc

Pietro Bonacossa is a Marketing Executive at Chiltern International in the USA. He holds a BA degree in International Trade from Auburn University and an MBA in Marketing from Georgia State University. Prior to joining Chiltern, he spent two years at Turner Broadcasting Systems, working as a Project Co-ordinator for CNN Headline News and as a Public Relations Liaison for CNN.com.


Dr Faiz Kermani is currently a Budgets, Proposals & Marketing Executive working in business development at Chiltern International. He previously worked in business development at CMR International, examining R&D productivity issues for pharmaceutical industry clients. He holds a PhD in Immunopharmacology from St Thomas' Hospital, London and a First Class honours degree in Pharmacology with Toxicology from King's College, London.


spacer
Pietro Bonacossa
spacer
spacer
spacer
Dr Faiz Kermani
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Surge of Indian biosimilars market forecast in 2019

16th April 2019: New data from CPhI shows that, despite ongoing reputational challenges, India’s biologics market is set for robust growth in 2019 driven by biosimilars production. The India specific findings from CPhI’s bio league tables predict strong ‘bio growth potential’ in India throughout 2019 in the build-up to the 13th edition of CPhI India 2019, which will take place at the India Expo Centre in Delhi NCR.
More info >>

White Papers

Mouse Models for Evaluation of Vaccines and Therapeutics Against Staphylococcal Infections

IBT Bioservices

Introduction Staphylococcus aureus (SA) is a ubiquitous, formidable Gram-positive pathogen associated with skin and soft tissue, as well as lifethreatening systemic infections. SA is a leading cause of hospital- and community-associated infections worldwide, affecting humans and animals. The wide range of pathologies reflects the diverse abilities of this microbe to escape the innate and adaptive immune response using virulence factors. Since its first emergence in the 1960s methicillin-resistant SA (MRSA) has become endemic in hospitals and healthcare settings worldwide. In the 1990s, community associated MRSA strains (CA-MRSA) emerged, and are spreading worldwide posing a major global challenge.
More info >>

 
Industry Events

World Pharma Week 2019

17-20 June 2019, Seaport World Trade Center, Boston

World Pharma Week will bring together a unique and international mix of large and medium pharmaceutical and biotech companies, CROs, leading universities and clinical research institutions, emerging companies and tool providers—making it a perfect meeting-place to share experience, foster collaborations across industry and academia, and evaluate emerging technologies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement